- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Dr. Reddy’s Laboratories Ltd ADR (RDY)
Dr. Reddy’s Laboratories Ltd ADR stock price live, this page displays NYSE RDY stock exchange data. View the RDY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Dr. Reddy’s Laboratories Ltd ADR real time stock price chart below.
What Is the Dr. Reddy’s Laboratories Ltd ADR Stock Price Today?
The Dr. Reddy’s Laboratories Ltd ADR stock price today is 13.32.
What Is the Stock Symbol for Dr. Reddy’s Laboratories Ltd ADR?
The stock symbol for Dr. Reddy’s Laboratories Ltd ADR is "RDY."
What Stock Exchange Does Dr. Reddy’s Laboratories Ltd ADR Trade On?
Dr. Reddy’s Laboratories Ltd ADR is listed and trades on the NYSE stock exchange.
Is Dr. Reddy’s Laboratories Ltd ADR a Good Stock to Buy?
Determining whether Dr. Reddy’s Laboratories Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RDY quote. (ISIN: US2561352038)
What Is the Dr. Reddy’s Laboratories Ltd ADR Stock Price Today?
The Dr. Reddy’s Laboratories Ltd ADR stock price today is 13.32.
What Is the Stock Symbol for Dr. Reddy’s Laboratories Ltd ADR?
The stock symbol for Dr. Reddy’s Laboratories Ltd ADR is "RDY."
What Stock Exchange Does Dr. Reddy’s Laboratories Ltd ADR Trade On?
Dr. Reddy’s Laboratories Ltd ADR is listed and trades on the NYSE stock exchange.
Is Dr. Reddy’s Laboratories Ltd ADR a Good Stock to Buy?
Determining whether Dr. Reddy’s Laboratories Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RDY quote. (ISIN: US2561352038)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.31
13.45
52 wk Range
12.26
16.17
RDY is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.3113.45
52 wk Range
12.2616.17
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.54%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.54%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RDY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
14.27
Upside
+7.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high P/E ratio relative to near-term earnings growth
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Dr. Reddy’s Laboratories Ltd ADR Company Profile
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy’s Laboratories Ltd ADR SWOT Analysis
Generics Giant Evolves | Dr. Reddy's outperforms in key markets, with strong growth in North America and India, while advancing its biosimilars pipeline for future expansion |
Financial Health | Robust performance with 12.37% revenue growth and 59.29% gross profit margin. InvestingPro analysis suggests stock undervaluation, indicating potential upside |
Market Dynamics | Stable generic drug pricing provides solid foundation for core business, allowing focus on volume growth and market share expansion in competitive landscape |
Analyst Outlook | Overweight rating maintained. Price targets range from $17 to $87, reflecting varied perspectives on Dr. Reddy's growth potential in generics and biosimilars |
Dr. Reddy’s Laboratories Ltd ADR Earnings Call Summary for Q3/2026
- Dr. Reddy's Q3 FY26 revenue reached $971 million, exceeding forecasts by 3.8% with 4.4% YoY growth, despite stock dipping 1.47% in premarket trading
- Strong performance in emerging markets (+32%) and India (+19%) offset North American generic business decline of 16% YoY, maintaining 53.6% gross profit margin
- Strategic product pipeline includes Semaglutide launch in India by March 21 and in Canada between February-May, with R&D spend projected at 7-8%
- CEO Erez Israeli highlighted double-digit growth in base business while preparing for 'very competitive markets'; company maintains $342 million net cash surplus
- Challenges include delayed US Rituximab launch and competitive pressures, though management projects double-digit growth across most markets
Last Updated: 2026-01-21, 10:24 a/m
Read Full TranscriptCompare RDY to Peers and Sector
Metrics to compare | RDY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRDYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.8x | 23.0x | −0.6x | |
PEG Ratio | 3.23 | 0.34 | 0.00 | |
Price/Book | 2.7x | 3.5x | 2.6x | |
Price / LTM Sales | 2.9x | 3.7x | 3.4x | |
Upside (Analyst Target) | 4.6% | 13.9% | 43.4% | |
Fair Value Upside | Unlock | 15.2% | 6.3% | Unlock |
Analyst Ratings
2 Buy
2 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 14.27
(+7.16% Upside)
Earnings
Latest Release
Jan 21, 2026
EPS / Forecast
14.52 / 0.1571
Revenue / Forecast
87.27B / 935.29M
People Also Watch
FAQ
What Is the Dr. Reddy’s Labs ADR (RDY) Stock Price Today?
The Dr. Reddy’s Labs ADR stock price today is 13.32
What Stock Exchange Does Dr. Reddy’s Labs ADR Trade On?
Dr. Reddy’s Labs ADR is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Dr. Reddy’s Labs ADR?
The stock symbol for Dr. Reddy’s Labs ADR is "RDY."
Does Dr. Reddy’s Labs ADR Pay Dividends? What’s The Current Dividend Yield?
The Dr. Reddy’s Labs ADR dividend yield is 0.54%.
What Is the Dr. Reddy’s Labs ADR Market Cap?
As of today, Dr. Reddy’s Labs ADR market cap is 10.94B.
What Is Dr. Reddy’s Labs ADR's Earnings Per Share (TTM)?
The Dr. Reddy’s Labs ADR EPS (TTM) is 67.93.
When Is the Next Dr. Reddy’s Labs ADR Earnings Date?
Dr. Reddy’s Labs ADR will release its next earnings report on May 08, 2026.
From a Technical Analysis Perspective, Is RDY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Dr. Reddy’s Labs ADR Stock Split?
Dr. Reddy’s Labs ADR has split 2 times.
How Many Employees Does Dr. Reddy’s Labs ADR Have?
Dr. Reddy’s Labs ADR has 27811 employees.
What is the current trading status of Dr. Reddy’s Labs ADR (RDY)?
As of Jan 29, 2026, Dr. Reddy’s Labs ADR (RDY) is trading at a price of 13.32, with a previous close of 13.32. The stock has fluctuated within a day range of 13.31 to 13.45, while its 52-week range spans from 12.26 to 16.17.
What Is Dr. Reddy’s Labs ADR (RDY) Price Target According to Analysts?
The average 12-month price target for Dr. Reddy’s Labs ADR is USD14.27, with a high estimate of USD16.76286585 and a low estimate of USD11.36127734. 2 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +7.16% Upside potential.
What Is the RDY After Hours Price?
RDY's last after hours stock price is 13.30, the stock has decreased by -0.02, or -0.15%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.